[go: up one dir, main page]

AR034091A1 - Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno - Google Patents

Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno

Info

Publication number
AR034091A1
AR034091A1 ARP000103450A ARP000103450A AR034091A1 AR 034091 A1 AR034091 A1 AR 034091A1 AR P000103450 A ARP000103450 A AR P000103450A AR P000103450 A ARP000103450 A AR P000103450A AR 034091 A1 AR034091 A1 AR 034091A1
Authority
AR
Argentina
Prior art keywords
straight
branched chain
group
strogen
receiver
Prior art date
Application number
ARP000103450A
Other languages
English (en)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of AR034091A1 publication Critical patent/AR034091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición farmacéutica que comprende un diluyente o vehículo aceptable para uso farmacéutico, una cantidad aceptable en términos terapéuticos de un modulador selectivo del receptor de estrógeno que tiene la fórmula general (1) donde R1 y R2 se seleccionan independientemente del grupo que consiste en hidrógeno, oxhidrilo, -OM (M se elige de entre el grupo que consiste en alquilo C1-4 de cadena lineal o ramificada, alquenilo C3-4 de cadena lineal o ramificada, alquinilo C3-4 de cadena lineal o ramificada) y una unidad convertible a oxhidrilo in vivo; G es -H ó -CH3; R3 es una especie que se selecciona del grupo consistente en pirrolidinilo, piperidino, morfolino, y NRaRb (Ra y Rb son independientemente hidrógeno, alquilo C1-6 de cadena lineal o ramificada, alquenilo C3-6 de cadena lineal o ramificada, y alquinilo C3-6 de cadena lineal o ramificada), y un precursor de esteroide sexual que se elige de entre el grupo que consiste en dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-3-eno-3b, 17b-diol y compuestos que se convierten a los anteriores in vivo. Métodos para el tratamiento médico y/o la prevención de la obesidad, la grasa abdominal y la resistencia a la insulina en animales de sangre caliente susceptibles, incluido el ser humano, que consisten en la administración de los moduladores selectivos de los receptores de estrógeno (SERM). También se describe una combinación de un SERM con una cantidad de estrógeno o un procursor de esteroides sexuales seleccionados del grupo formado por dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-3-eno-3b, 17b-diol y compuestos convertidos in vivo en uno de los precursores mencionados o estrógeno. Compuesto que tiene la estructura molecular de fórmula (2).
ARP000103450A 1999-07-06 2000-07-06 Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno AR034091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06

Publications (1)

Publication Number Publication Date
AR034091A1 true AR034091A1 (es) 2004-02-04

Family

ID=22499734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103450A AR034091A1 (es) 1999-07-06 2000-07-06 Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno

Country Status (25)

Country Link
US (2) US6710059B1 (es)
EP (1) EP1196163B1 (es)
JP (1) JP4790178B2 (es)
KR (1) KR101141763B1 (es)
CN (1) CN1390126B (es)
AR (1) AR034091A1 (es)
AT (1) ATE447947T1 (es)
AU (3) AU5957500A (es)
BR (1) BR0012354A (es)
CA (1) CA2376158C (es)
DE (1) DE60043305D1 (es)
DK (1) DK1196163T3 (es)
HK (1) HK1046240B (es)
HU (1) HU230543B1 (es)
IL (2) IL147485A0 (es)
MX (1) MX270786B (es)
MY (1) MY134574A (es)
NO (1) NO329614B1 (es)
NZ (1) NZ516453A (es)
PL (1) PL208972B1 (es)
RU (3) RU2327461C2 (es)
TR (2) TR200403328T2 (es)
TW (1) TWI359015B (es)
WO (1) WO2001001969A2 (es)
ZA (1) ZA200200085B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
TR200403328T2 (tr) * 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
MXPA04002249A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
AU2003294185A1 (en) * 2002-12-13 2004-07-09 N.V. Nutricia Method and composition for inhibiting carbohydrate digestion
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
CN106138065A (zh) * 2004-10-20 2016-11-23 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
KR20080031037A (ko) * 2005-06-29 2008-04-07 와이어쓰 결합형 에스트로겐과 바제독시펜의 제형
WO2007011708A2 (en) * 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
AU2007243268B2 (en) 2006-04-26 2013-06-13 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CN101678388B (zh) * 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
JP5443336B2 (ja) * 2007-04-17 2014-03-19 ミセル テクノロジーズ、インコーポレイテッド 生分解性層を有するステント
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
BRPI0910969B8 (pt) * 2008-04-17 2021-06-22 Micell Technologies Inc dispositivo
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111196A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Peripheral stents having layers
CA2756388C (en) * 2009-03-23 2015-10-27 Micell Technologies, Inc. Biodegradable polymers with low acidic impurity
WO2010111232A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
EP2413847A4 (en) * 2009-04-01 2013-11-27 Micell Technologies Inc COATED STENTS
EP2419058B1 (en) 2009-04-17 2018-02-28 Micell Technologies, Inc. Stents having controlled elution
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2455082A4 (en) * 2009-07-16 2012-12-19 Univ Kyushu Nat Univ Corp INSULIN-PRODUCING CELL INDUCTOR, GLUCOSE-UP AMPLIFIERS AND THERAPY AGENTS FOR DIABETES OR COMPLICATIONS IN CONNECTION WITH DIABETES
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
WO2014165264A1 (en) 2013-03-12 2014-10-09 Micell Technologies, Inc. Bioabsorbable biomedical implants
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA3006683A1 (en) * 2015-12-22 2017-06-29 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
US20180207097A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Non-toxic vehicle to solubilize, deliver, and obtain biological activity of steroid hormones at cell, tissue, and organ targets, in vitro and in vivo
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CA2091102C (en) * 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
NZ260790A (en) 1993-06-24 1997-06-24 Lilly Co Eli Antiestrogen compositions for treatment of diabetes mellitus
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
AU8433898A (en) * 1997-07-10 1999-02-08 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
UA70925C2 (uk) * 1997-08-15 2004-11-15 Дюк Юнівесіті Спосіб лікування естрогенстимульованого раку
ATE218348T1 (de) * 1997-10-08 2002-06-15 Genesiscosmetics Rights & Lice Straffung und/oder verkleinerung von fettzellen- haltigen körperpartien
JP2002515431A (ja) 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション エストロゲンと組み合わせる２−フェニル−１−［４−（２−アミノエトキシ）ベンジルオキシ］インドール
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
TR200403328T2 (tr) 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.

Also Published As

Publication number Publication date
TWI359015B (en) 2012-03-01
US8609695B2 (en) 2013-12-17
PL208972B1 (pl) 2011-07-29
JP4790178B2 (ja) 2011-10-12
WO2001001969A2 (en) 2001-01-11
AU2009200258A1 (en) 2009-02-26
MY134574A (en) 2007-12-31
ATE447947T1 (de) 2009-11-15
MX270786B (es) 2009-10-08
IL195860A (en) 2013-06-27
JP2003503446A (ja) 2003-01-28
HUP0202363A3 (en) 2005-02-28
WO2001001969A3 (en) 2001-08-02
NO20020037D0 (no) 2002-01-04
CA2376158C (en) 2011-03-15
AU2009200258B2 (en) 2012-01-12
DE60043305D1 (de) 2009-12-24
RU2008101793A (ru) 2009-07-27
HU230543B1 (hu) 2016-11-28
NO329614B1 (no) 2010-11-22
BR0012354A (pt) 2002-04-02
AU5957500A (en) 2001-01-22
ZA200200085B (en) 2003-06-25
US20040034000A1 (en) 2004-02-19
EP1196163B1 (en) 2009-11-11
EP1196163A2 (en) 2002-04-17
NO20020037L (no) 2002-03-04
CA2376158A1 (en) 2001-01-11
RU2519642C2 (ru) 2014-06-20
HK1046240B (en) 2010-09-30
HUP0202363A2 (en) 2002-10-28
TR200403328T2 (tr) 2005-03-21
CN1390126A (zh) 2003-01-08
RU2327461C2 (ru) 2008-06-27
US6710059B1 (en) 2004-03-23
NZ516453A (en) 2004-04-30
MXPA02000075A (es) 2003-05-23
AU2005229713A1 (en) 2005-12-01
KR101141763B1 (ko) 2012-05-08
RU2013148518A (ru) 2015-05-10
HK1046240A1 (en) 2003-01-03
DK1196163T3 (da) 2010-03-29
TR200502284T2 (tr) 2005-08-22
RU2636498C2 (ru) 2017-11-23
PL352993A1 (en) 2003-09-22
TW200803838A (en) 2008-01-16
CN1390126B (zh) 2012-06-13
IL147485A0 (en) 2002-08-14
KR20020020776A (ko) 2002-03-15

Similar Documents

Publication Publication Date Title
AR034091A1 (es) Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno
Girgis et al. Therapies for musculoskeletal disease: can we treat two birds with one stone?
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
GEP20053586B (en) Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
NO20003546D0 (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
ATE347365T1 (de) Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
ES2458218T9 (es) Modulador selectivo del receptor de estr�genos en combinación con deshidroepiandrosterona (DHEA) o análogos
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
RU2010121160A (ru) Спиросоединения и их фармацевтическое применение
UY28150A1 (es) Agentes terapeuticos
PE20021147A1 (es) Composicion de alimento para mascotas que contiene agentes de gelacion semi-refinados
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
AR046756A1 (es) Derivados de hidronopol como agonistas de receptores orl-1 humanos.
CN1681513A (zh) 用于癌症治疗的含有雌四醇衍生物的药物组合物
AR034392A1 (es) Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen
AR026655A1 (es) Nuevos esteroides con actividad androgenica y su uso como antinconceptivos masculinos y para tratar la insuficiencia androgenica
TW200612962A (en) Estriol and estetrol prodrugs
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
AR003002A1 (es) Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones
AR034194A1 (es) Un compuesto esteroide, su uso, una composicion farmaceutica que lo comprende y un kit para la anticoncepcion masculina
PE20030186A1 (es) Compuestos ciclicos fusionados como moduladores del receptor hormonal nuclear
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
AR035590A1 (es) Derivados 8 beta-sustituidos de 11beta-pentil- y 11beta-hexil-estra-1,3,5 (10)-trieno, las composiciones farmaceuticas que los contienen y el uso de estos derivados para preparar medicamentos

Legal Events

Date Code Title Description
FC Refusal